The Mechanism and Research Progress of Inflammation in Heart Failure with Preserved Ejection FractionDing Rong1, Li Jinyu1△, Pan Jiayin1, Wu Mengyao1,Wang Weiwei1,Zheng Xin1

Corresponding author: Li Jinyu, 63426497@qq.com

DOI: 10.12201/bmr.202603.00045

•  

  Abstract: Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure characterized primarily by abnormal left ventricular diastolic function. As a highly heterogeneous clinical syndrome, its clinical manifestations and long?term outcomes cannot be fully explained by cardiac abnormalities alone. The pathogenesis of HFpEF involves the interplay of multiple factors, including myocardial fibrosis, microvascular dysfunction, metabolic disorders, and systemic inflammatory responses. Recent studies have further established that inflammatory signaling pathways represent one of the key mechanisms driving the progression of HFpEF. At present, the pathophysiological mechanisms underlying HFpEF remain incompletely understood, and effective therapeutic strategies targeting the inflammatory component are still lacking. This review aims to systematically summarize the mechanistic roles of inflammation in HFpEF, recent advances in related biomarkers, and the current landscape of anti?inflammatory therapeutic approaches.

  Key words: Heart failure with preserved ejection fraction; Inflammation; Biomarkers.

  Submit time: 12 March 2026

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• LI JIE. Research Advances in Heart Failure with Preserved Ejection Fraction Complicated by Chronic Kidney Disease. 2025. doi: 10.12201/bmr.202504.00077

  HAN Chenyuan. Analysis and evaluation of guideline-directed medical therapy in chronic heart failure inpatients with reduced ejection fraction in a third level hospital. 2025. doi: 10.12201/bmr.202507.00076

  wang zhong. Plasma C1q/ tumor necrosis factor-associated protein 6 and systemic inflammatory response index levels in patients with heart failure and their clinical significance. 2025. doi: 10.12201/bmr.202501.00060

  paerhati·tuerxun. . 2025. doi: 10.12201/bmr.202507.00038

  李明峻, Zhai Ning. Advances and prospects of artificial intelligence in precision phenotyping of heart failure. 2025. doi: 10.12201/bmr.202512.00030

  WU Xiayang. The mechanisms of action of SGLT2i in the treatment of heart failure and recent research advances. 2025. doi: 10.12201/bmr.202507.00052

  guoxinyao, yanshuang, fengyanhong. . 2025. doi: 10.12201/bmr.202512.00047

  苏巧玲, Weng Jinlong. Exploring the Potential Mechanism of Astragalus and Salvia Decoction in Intervention of Chronic Heart Failure Based on the Method of Reinforcing Qi and Activating Blood. 2026. doi: 10.12201/bmr.202601.00043

  Qiu Xiaoqin, Wei Jisi, Qiu Xinyu, Liu Na, Chen Sifan. Summary of the scope of symptom groups in patients with heart failure. 2025. doi: 10.12201/bmr.202501.00046

  HEXin, matiantian, yuanyuepeng, zhuyuanheng, xuyiguo, wangweilong. Exploration of the pathogenesis of vascular depression based on the theory of heart-brain homoeopathy in the treatment of vascular depressionLU Caiju1,HE Xin1,YUAN Yuepeng2,MA Tiantian1,ZHU Yuanheng1,XU Yiguo2,WANG Weilong2. 2025. doi: 10.12201/bmr.202507.00080

• ID	Submit time	Number	Download
  1	2026-01-09	10.12201/bmr.202603.00045V1	Download

• Public  Anonymous  To author only Submit Comments